Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315780710> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4315780710 endingPage "e275" @default.
- W4315780710 startingPage "e275" @default.
- W4315780710 abstract "Objective: Congestive heart failure (CHF) represents an extreme burden to the public healthcare worldwide. The incidence and prevalence of chronic kidney disease (CKD) is also increasing and CKD is known as one of the strongest risk factors for the development of CHF. CHF coexists with CKD in approximately half of CHF patients and results in a poor survival rate. The aim of this study was therefore to examine if the addition of endothelin type A (ETA) receptor antagonist atrasentan (5 mg/kg/day) to the angiotensin-converting enzyme inhibitor (ACEi trandolapril; 2 mg/L) will bring additional beneficial effects. Design and Methods: CKD was induced by 5/6 renal mass reduction (5/6 NX) at the age of 8 weeks and CHF was elicited by volume overload achieved by the creation of aortocaval fistula (ACF) four weeks later in normotensive Hannover Sprague Dawley rats. The follow-up was 24 weeks after the first intervention (5/6 NX). The treatment regimens were initiated 6 weeks after 5/6 NX and 2 weeks after ACF. Results: The final survival in untreated group was 15%. The treatment with ETA receptor antagonist alone or ACEi alone and the combined treatment improved the survival rate to 64%, 71% and 75%, respectively, with no significant difference between the combination and either single treatment regimen. At the end of the study, atrasentan or trandolapril given alone partially reduced albuminuria, but had no effect on albumin/creatinine ratio. In contrast, both parameters were substantially improved by the combined treatment which caused ∼45 % reduction in albuminuria. Moreover, it also reduced markers of renal damage. Conclusions: Our results demonstrated that the treatment with ETA receptor antagonist attenuated the mortality related to CKD or CHF and that the addition of ETA receptor antagonist to the standard blockade of renin angiotensin system by ACEi exhibited additional renoprotective actions." @default.
- W4315780710 created "2023-01-13" @default.
- W4315780710 creator A5061612754 @default.
- W4315780710 creator A5061685239 @default.
- W4315780710 creator A5070005942 @default.
- W4315780710 creator A5072638292 @default.
- W4315780710 creator A5078212495 @default.
- W4315780710 date "2023-01-01" @default.
- W4315780710 modified "2023-10-18" @default.
- W4315780710 title "PS-BPB05-2: ENDOTHELIN A RECEPTOR BLOCKADE INCREASES RENOPROTECTION IN EXPERIMENTAL MODEL OF CONGESTIVE HEART FAILURE COMBINED WITH CHRONIC KIDNEY DISEASE" @default.
- W4315780710 doi "https://doi.org/10.1097/01.hjh.0000915544.76584.a9" @default.
- W4315780710 hasPublicationYear "2023" @default.
- W4315780710 type Work @default.
- W4315780710 citedByCount "0" @default.
- W4315780710 crossrefType "journal-article" @default.
- W4315780710 hasAuthorship W4315780710A5061612754 @default.
- W4315780710 hasAuthorship W4315780710A5061685239 @default.
- W4315780710 hasAuthorship W4315780710A5070005942 @default.
- W4315780710 hasAuthorship W4315780710A5072638292 @default.
- W4315780710 hasAuthorship W4315780710A5078212495 @default.
- W4315780710 hasBestOaLocation W43157807101 @default.
- W4315780710 hasConcept C126322002 @default.
- W4315780710 hasConcept C126894567 @default.
- W4315780710 hasConcept C134018914 @default.
- W4315780710 hasConcept C144980905 @default.
- W4315780710 hasConcept C159641895 @default.
- W4315780710 hasConcept C164705383 @default.
- W4315780710 hasConcept C170493617 @default.
- W4315780710 hasConcept C24595384 @default.
- W4315780710 hasConcept C27016395 @default.
- W4315780710 hasConcept C2778198053 @default.
- W4315780710 hasConcept C2778653478 @default.
- W4315780710 hasConcept C2778728240 @default.
- W4315780710 hasConcept C2779611605 @default.
- W4315780710 hasConcept C2780306776 @default.
- W4315780710 hasConcept C71924100 @default.
- W4315780710 hasConcept C84393581 @default.
- W4315780710 hasConceptScore W4315780710C126322002 @default.
- W4315780710 hasConceptScore W4315780710C126894567 @default.
- W4315780710 hasConceptScore W4315780710C134018914 @default.
- W4315780710 hasConceptScore W4315780710C144980905 @default.
- W4315780710 hasConceptScore W4315780710C159641895 @default.
- W4315780710 hasConceptScore W4315780710C164705383 @default.
- W4315780710 hasConceptScore W4315780710C170493617 @default.
- W4315780710 hasConceptScore W4315780710C24595384 @default.
- W4315780710 hasConceptScore W4315780710C27016395 @default.
- W4315780710 hasConceptScore W4315780710C2778198053 @default.
- W4315780710 hasConceptScore W4315780710C2778653478 @default.
- W4315780710 hasConceptScore W4315780710C2778728240 @default.
- W4315780710 hasConceptScore W4315780710C2779611605 @default.
- W4315780710 hasConceptScore W4315780710C2780306776 @default.
- W4315780710 hasConceptScore W4315780710C71924100 @default.
- W4315780710 hasConceptScore W4315780710C84393581 @default.
- W4315780710 hasIssue "Suppl 1" @default.
- W4315780710 hasLocation W43157807101 @default.
- W4315780710 hasLocation W43157807102 @default.
- W4315780710 hasOpenAccess W4315780710 @default.
- W4315780710 hasPrimaryLocation W43157807101 @default.
- W4315780710 hasRelatedWork W1966732677 @default.
- W4315780710 hasRelatedWork W2046899919 @default.
- W4315780710 hasRelatedWork W2058514018 @default.
- W4315780710 hasRelatedWork W2124543160 @default.
- W4315780710 hasRelatedWork W2140445493 @default.
- W4315780710 hasRelatedWork W2282940954 @default.
- W4315780710 hasRelatedWork W3011378569 @default.
- W4315780710 hasRelatedWork W3133946270 @default.
- W4315780710 hasRelatedWork W3160253811 @default.
- W4315780710 hasRelatedWork W4280508227 @default.
- W4315780710 hasVolume "41" @default.
- W4315780710 isParatext "false" @default.
- W4315780710 isRetracted "false" @default.
- W4315780710 workType "article" @default.